Seres Therapeutics, Inc. (MCRB) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 11 recommend buying, 3 recommend holding, and 4 recommend selling.
The analyst consensus price target for MCRB is $1.25, representing a -85.5% downside from the current price of $8.61. Price targets range from a low of $1.25 to a high of $1.25.
